fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies
- PMID: 24764718
- PMCID: PMC3997466
- DOI: 10.3747/co.21.1803
fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies
Abstract
Patients with neurofibromatosis type 1 (nf1) are at increased risk for both benign and malignant tumours, and distinguishing the malignant potential of an individual tumour is a common clinical problem in these patients. Here, we review two cases of uncommon malignancies (Hodgkin lymphoma and mediastinal germ-cell tumour) in patients with nf1. Although (18)F-fluorodeoxyglucose positron-emission tomography (fdg-pet) has been used to differentiate benign neurofibromas from malignant peripheral nerve sheath tumours, fdg-pet characteristics for more rare tumours have been poorly described in children with nf1. Here, we report the role of pet imaging in clinical decision-making in each case. In nf1, fdg-pet might be useful in the clinical management of unusual tumour presentations and might help to provide information about the malignant potential of uncommon tumours.
Keywords: Hodgkin lymphoma; Klinefelter syndrome; Neurofibromatosis type 1; germ-cell tumours; pediatric oncology.
Figures


Similar articles
-
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7. doi: 10.1136/jnnp.68.3.353. J Neurol Neurosurg Psychiatry. 2000. PMID: 10675220 Free PMC article.
-
[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.Ann Oncol. 2008 Feb;19(2):390-4. doi: 10.1093/annonc/mdm450. Epub 2007 Oct 11. Ann Oncol. 2008. PMID: 17932395
-
[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.Eur J Nucl Med Mol Imaging. 2009 May;36(5):751-7. doi: 10.1007/s00259-008-1038-0. Epub 2009 Jan 14. Eur J Nucl Med Mol Imaging. 2009. PMID: 19142634
-
Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.Rofo. 2015 Dec;187(12):1084-92. doi: 10.1055/s-0035-1553505. Epub 2015 Sep 2. Rofo. 2015. PMID: 26333104 Review.
-
The Use of PET in the Evaluation of Tumors in Children with Neurofibromatosis Type 1.PET Clin. 2008 Oct;3(4):531-49. doi: 10.1016/j.cpet.2009.04.005. Epub 2009 Jul 25. PET Clin. 2008. PMID: 27156818 Review.
References
-
- Ferner RE, Lucas JD, O’Doherty MJ, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18fdg pet) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68:353–7. doi: 10.1136/jnnp.68.3.353. - DOI - PMC - PubMed
-
- Ferner RE, Golding JF, Smith M, et al. 18F 2-fluoro-2-deoxyd-glucose positron emission tomography (fdg pet) as a diagnostic tool for neurofibromatosis 1 (nf1) associated malignant peripheral nerve sheath tumours (mpnsts): a long-term clinical study. Ann Oncol. 2008;19:390–4. doi: 10.1093/annonc/mdm450. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous